Taysha Gene Therapies Shares Outstanding 2020-2024 | TSHA

Taysha Gene Therapies shares outstanding from 2020 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Taysha Gene Therapies Annual Shares Outstanding
(Millions of Shares)
2023 116
2022 44
2021 38
2020 18
2019
Taysha Gene Therapies Quarterly Shares Outstanding
(Millions of Shares)
2024-03-31 231
2023-12-31 116
2023-09-30 126
2023-06-30 64
2023-03-31 63
2022-12-31 44
2022-09-30 41
2022-06-30 40
2022-03-31 38
2021-12-31 38
2021-09-30 38
2021-06-30 37
2021-03-31 37
2020-12-31 18
2020-09-30 12
2020-06-30 11
2020-03-31 11
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.400B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.040B 6.57
Dr Reddy's Laboratories (RDY) India $13.038B 19.39
BridgeBio Pharma (BBIO) United States $4.901B 0.00
Bausch Health Cos (BHC) Canada $2.746B 2.12
Amphastar Pharmaceuticals (AMPH) United States $1.937B 11.65
Supernus Pharmaceuticals (SUPN) United States $1.663B 0.00
Personalis (PSNL) United States $0.200B 0.00
Assembly Biosciences (ASMB) United States $0.083B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.023B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00